Kaya Holdings, INC

Kaya Holdings, Inc. announced the appointment of seasoned attorney Richard D. Seay to its board of directors, effective November 25, 2025.

Kaya Holdings, Inc. announced a significant debt-to-equity conversion, resulting in a change of control, as it pivots towards a digital assets treasury strategy.

Kaya Holdings, Inc. has engaged Greentree Financial Group and Conduit Advisors to develop a new cryptocurrency operating subsidiary and implement a Digital Assets Treasury strategy.

Carrie Schwarz resigned from her position as a director of Kaya Holdings, Inc., effective April 24, 2025.

Kaya Holdings has announced the launch of its psilocybin treatment center, The Sacred Mushroom, in Portland, Oregon, as reported by television station KATU.

Kaya Holdings has amended its Certificate of Incorporation to increase the number of authorized common stock shares from 500 million to 1.5 billion.

Kaya Holdings reported a significantly increased net loss for the nine months ended September 30, 2025, driven by non-cash derivative expenses, while strategically exiting its cannabis operations to focus on psychedelic treatments and digital assets.

Kaya Holdings, Inc. reported a significantly wider net loss for Q2 2025, driven by increased derivative liabilities and early-stage psychedelic business development, despite exiting its cannabis retail operations.

Kaya Holdings, Inc. reports a net loss for Q1 2025 as it transitions from cannabis retail to psychedelic treatment facilities, with a focus on The Sacred Mushroom facility.

Kaya Holdings reports a net loss for Q3 2024, primarily due to changes in derivative liabilities, as it transitions from cannabis operations to focus on its new psilocybin treatment center.

Kaya Holdings, Inc. has filed an amended quarterly report for the period ending June 30, 2024, to reflect the completion of a required accounting review, reporting a net income primarily due to changes in derivative liabilities.

Kaya Holdings reports a net income of $432,210 for the quarter ending June 30, 2024, primarily due to derivative liabilities, while transitioning from cannabis to psilocybin operations.

Kaya Holdings' amended 10-K filing reveals discontinued retail cannabis operations, a shift towards psychedelic medicine, and substantial doubt about the company's ability to continue as a going concern.

Kaya Holdings, a holding company in the wellness sector, reports a net loss for 2024 and suspends payroll due to capital constraints, despite progress in its psychedelic treatment center operations.

Kaya Holdings has filed an amendment to its 2023 Form 10-K solely to correct an error in the date of the executive certification.

Kaya Holdings is transitioning towards psychedelic therapeutics with the planned opening of 'The Sacred Mushroom' treatment center, while reporting a net income for 2023 primarily due to derivative liability adjustments.

Kaya Holdings, Inc. files an amendment to its registration statement for the resale of up to 25 million shares of common stock by selling stockholders, as the company focuses on its wellness and mental health operations.

Kaya Holdings, Inc. has filed a registration statement for the resale of up to 25 million shares of its common stock by selling stockholders, as the company focuses on its wellness and mental health operations.